Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone

• Published in: Head & neck 2016-04, Vol.38 (S1), p.E949-E953
• Main Authors: Shinomiya, Hirotaka, Hasegawa, Shingo, Yamashita, Daisuke, Ejima, Yasuo, Kenji, Yoshida, Otsuki, Naoki, Kiyota, Naomi, Sakakibara, Shunsuke, Nomura, Tadashi, Hashikawa, Kazunobu, Kohmura, Eiji, Sasaki, Ryohei, Nibu, Ken-ichi
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Neoplasms - therapy; Carcinoma, Squamous Cell - therapy; Chemoradiotherapy; cisplatin; Cisplatin - therapeutic use; concomitant chemoradiotherapy; Disease-Free Survival; docetaxel; ear cancer; Female; Fluorouracil - therapeutic use; Head and Neck Neoplasms - therapy; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids - therapeutic use; temporal bone; Temporal Bone - pathology
• ISSN: 1043-3074; 1097-0347
• DOI: 10.1002/hed.24133

ABSTRACT Background The purpose of this study was to analyze outcomes for the treatment of locally advanced temporal bone cancer by means of concomitant chemoradiotherapy (CCRT) with a combination of cisplatin (CDDP), 5‐fluorouracil (5‐FU), and docetaxel (TPF). Methods Between 2006 and 2011, 34 patients with squamous cell carcinoma of the temporal bone were treated at Kobe University Hospital. Medical records were retrospectively reviewed to obtain information concerning patient characteristics, extent of disease, treatment, adverse events, and oncologic results. Results Ten patients were treated with CCRT using TPF regimen. The 5‐year overall survival rate and disease‐free survival rate were both 60%. Of special interest is that even for patients with unresectable T4 disease, the 5‐year overall survival rate was 56%. Conclusion The results of our study indicate that CCRT with TPF for locally advanced temporal bone cancer is an effective and promising regimen. © 2015 Wiley Periodicals, Inc. Head Neck 38: E949–E953, 2016